Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas.

Journal of neuropathology and experimental neurology - 22 Mar 2021

Dahl Nathan A, Donson Andrew M, Sanford Bridget, Wang Dong, Walker Faye M, Gilani Ahmed, Foreman Nicholas K, Tinkle Christopher L, Baker Suzanne J, Hoffman Lindsey M, Venkataraman Sujatha, Vibhakar Rajeev

Abstract excerpt

Diffuse midline gliomas (DMGs) are incurable pediatric tumors with extraordinarily limited treatment options. Decades of clinical trials combining conventional chemotherapies with radiation therapy have failed to improve these outcomes, demonstrating the need to identify and validate druggable biologic targets within this disease. NTRK1/2/3 fusions are found in a broad range of pediatric cancers, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Stem Neoplasms
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatal Outcome

Share to Glioma

Share to Jumonji Domain-Containing Histone Demethylases

Share to Membrane Glycoproteins

Share to Receptor, trkB

Share to Receptor, trkC

Source

Open in PubMed Open full text

Identifiers

PMID: 33749791
DOI: 10.1093/jnen/nlab016
PMCID: PMC7985828

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas.PMID 33749791Read ↗

NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitorsSemantic proximity Read ↗

NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical OutcomeSemantic proximity Read ↗

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted TherapeuticsSemantic proximity Read ↗

Diffuse pediatric high-grade glioma of methylation-based RTK2A and RTK2B subclasses present distinct radiological and histomolecular features including Gliomatosis cerebri phenotype.Semantic proximity Read ↗

Cooperativity between H3.3K27M and PDGFRA poses multiple therapeutic vulnerabilities in human iPSC-derived diffuse midline glioma avatarsSemantic proximity Read ↗

Extraneural Metastases of Diffuse Midline Glioma, H3 K27M-Mutant at Diagnosis: Case Report, Review of the Literature, and Identifying Targetable Alterations.Semantic proximity Read ↗

Advances in the biology and treatment of pediatric central nervous system tumors.Semantic proximity Read ↗

Therapeutic Targets in Diffuse Midline Gliomas—An Emerging LandscapeSemantic proximity Read ↗

New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline GliomaSemantic proximity Read ↗

Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsSemantic proximity Read ↗

Survival analysis of adult midline-located gliomas and diffuse midline gliomas: beyond the H3K27 mutation paradigm.Semantic proximity Read ↗

Single-cell multi-omic analyses resolve the cellular diversity of ALK/ROS1/MET/NTRK-fused gliomas in infants and older childrenSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.